Article
Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial.
Arteriosclerosis, thrombosis, and vascular biology - 1 Jan 2026
Xue Liying, Bhattacharya Romit, Uddin Md Mesbah, Nakao Tetsushi, Zou Roger, Patel Aniruddh, Haidermota Sara, Niroula Abhishek, Viscosi Victoria, Postupaka Darina, Bhatnagar Aarushi, Finneran Phoebe, Bernardo Rachel, Diggs Marissa R, Fitch Kathleen V, Chu Sarah M, McCallum Sara, Currier Judith S, Fichtenbaum Carl J, Malvestutto Carlos D, Aberg Judith A, Bloomfield Gerald S, Ribaudo Heather J, Zanni Markella V, Libby Peter, Hornsby Whitney, Lu Michael T, Douglas Pamela S, Grinspoon Steven K, Natarajan Pradeep
Abstract excerpt
BACKGROUND: People with HIV (PWH) experience higher cardiovascular disease event rates not fully explained by traditional risk factors. Clonal hematopoiesis of indeterminate potential (CHIP), an emerging risk factor for cardiovascular disease in the general population, has been reported to be more prevalent in PWH. METHODS: Using high-coverage targeted CHIP sequencing in the REPRIEVE (Randomized Trial to Prevent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.